Thyroid medications replace deficient hormones in hypothyroidism or suppress excessive hormone production in hyperthyroidism, restoring metabolic homeostasis. Thyroid disorders are among the most common endocrine conditions, with hypothyroidism affecting up to 5 percent of the population and hyperthyroidism affecting approximately 1 percent. Appropriate pharmacotherapy normalizes thyroid function, alleviates symptoms, and prevents long-term complications of thyroid dysfunction.

What Is Thyroid Pharmacotherapy?

Thyroid hormone synthesis and release are regulated by the hypothalamic-pituitary-thyroid axis. Thyrotropin-releasing hormone from the hypothalamus stimulates pituitary release of thyroid-stimulating hormone, which drives thyroidal production of thyroxine and triiodothyronine. Pharmacological intervention aims to either replace deficient hormone or block excessive production, with therapy tailored to the underlying etiology.

Drug Classes and Mechanisms

Levothyroxine is synthetic T4 and the standard of care for hypothyroidism. It is converted peripherally to the active hormone T3 by deiodinases, providing physiologic hormone replacement with once-daily dosing. Liothyronine is synthetic T3 used in specific circumstances such as myxedema coma or when peripheral conversion is impaired. Desiccated thyroid contains both T4 and T3 from animal sources and is occasionally used but not recommended as first-line therapy due to variable potency and supraphysiologic T3 levels. For hyperthyroidism, thionamides include methimazole and propylthiouracil, which inhibit thyroid peroxidase, reducing hormone synthesis. Propylthiouracil also inhibits peripheral T4-to-T3 conversion. Radioactive iodine is taken up by thyroid follicular cells and emits beta radiation, causing progressive thyroid ablation. Beta-blockers (propranolol, atenolol) are used adjunctively to control adrenergic symptoms of thyrotoxicosis including tachycardia, tremor, and anxiety.

Therapeutic Uses

Levothyroxine is indicated for all forms of hypothyroidism including primary (Hashimoto thyroiditis), central (pituitary insufficiency), and subclinical hypothyroidism with TSH above treatment thresholds. Treatment is monitored by measuring TSH levels, with a goal of 0.5 to 2.5 mIU/L for most patients. Methimazole is the preferred thionamide for Graves disease due to its longer half-life and lower hepatotoxicity risk; propylthiouracil is reserved for the first trimester of pregnancy, thyroid storm, and patients with adverse reactions to methimazole. Radioactive iodine is a definitive treatment for Graves disease and toxic nodular goiter.

Adverse Effects

Levothyroxine at appropriate doses has minimal adverse effects; overreplacement causes iatrogenic thyrotoxicosis with tachycardia, anxiety, insomnia, and bone loss, while underreplacement permits hypothyroid symptoms. Methimazole causes rash, arthralgia, and agranulocytosis (rare but serious). Propylthiouracil carries a risk of severe hepatotoxicity and is avoided in children and adults unless methimazole is not tolerated. Radioactive iodine frequently causes permanent hypothyroidism requiring lifelong levothyroxine therapy.

Key Clinical Considerations

Levothyroxine absorption is affected by food, calcium and iron supplements, and medications including proton pump inhibitors. It should be taken on an empty stomach 30 to 60 minutes before breakfast. TSH monitoring should occur 6 to 8 weeks after dose changes. Pregnancy increases levothyroxine requirements, and TSH should be maintained within trimester-specific targets. Thyroid storm is a medical emergency requiring high-dose thionamides, beta-blockers, corticosteroids, and supportive care.

Conclusion

Levothyroxine provides safe and effective hormone replacement for hypothyroidism when properly dosed and monitored. Thionamides and radioactive iodine offer well-established options for managing hyperthyroidism, with treatment choice guided by patient age, disease severity, and preference. Regular monitoring of thyroid function tests ensures optimal dosing and early detection of treatment-related complications.